News News Details

CoreRay’s 3 Key Products Secure EU CE Certification

Date: 2025-10-23
Views: 0
Recently, three core interventional access products independently developed by CoreRay Medical have successfully obtained EU CE certification:
  • Zhipeng Single-use Interventional Microcatheter

  • Zhiguan Peripheral Vascular Microguide Wire

  • Ruishen Balloon Dilatation Catheter

This marks CoreRay’s first EU CE certification since its founding, signifying international authoritative recognition of its R&D capabilities and quality system, and laying a solid foundation for entering the European and global markets.
EU CE certification is a globally recognized gold standard for medical device safety and performance, serving as the mandatory passport to the EU and European Free Trade Area. With stringent requirements, it represents a global threshold of high standards, high value, and high trust, confirming that the products:
  1. Meet the highest requirements of the EU Medical Device Regulation (MDR) in safety and performance.

  2. Gain free circulation in 30+ EU/EEA countries.

  3. Boost confidence among professional users and enhance global market recognition.

  4. Support domestic bidding policies encouraging innovative devices with international accreditation.

Developed on CoreRay’s proprietary B-E-S-T platform, the three products are engineered for complex vascular lesions, delivering superior support, crossing ability, and precision:
  • Zhipeng Microcatheter: High torque & high flow, 1:1 torque control in tortuous vessels.

  • Zhiguan Microguide Wire: Nitinol core with core-to-tip design for excellent trackability and kink resistance.

  • Ruishen Balloon Dilatation Catheter: High-pressure non-compliant balloon with tapered tip for precise dilation.

With CE certification, CoreRay will compete globally with leading brands, exemplifying the strength of China’s medical device innovation going global.


Related News / Recommended news More
2026 - 03 - 24
In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...
2026 - 03 - 25
Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...
2026 - 03 - 06
Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...
2026 - 03 - 05
The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务